Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Fundação de Apoio ao Ensino Pesquisa e Assitência do HCFMRPUSP | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the effects of anterior chamber paracentesis, brimonidine and oral acetazolamide to reduce intra-ocular pressure variations after intravitreal bevacizumab injection.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | No Intervention | Patients submitted to 1,5 mg/0,06 ml intravitreal injection of bevacizumab and no treatment for intraocular pressure elevation | |
| 2 | Experimental | Acetazolamide: 250 mg of oral acetazolamide 1 hour before intravitreal bevacizumab injection |
|
| 3 | Experimental | topic brimonidine tartarate: one drop of brimonidine tartarate 1 hour before intravitreal bevacizumab injection |
|
| 4 | Experimental | anterior chamber paracentesis: anterior chamber paracentesis immediately after intravitreal bevacizumab |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Acetazolamide | Drug | 250 mg 1 hour before intravitreal injection |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Intraocular pressure (mmHg) | 1 hour and, 3 minutes before IVI. 3,10,20, 30 minutes after IVI |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Rodrigo Jorge, MD | University of Sao Paulo | Study Chair |
| Marco A Bonini-Filho, MD | University of Sao Paulo | Principal Investigator |
| Bianka Y Katayama, MD | Clinic´s Hospital, Ribeirão Preto Medical School, University of São Paulo | Study Director |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Brimonidine tartarate | Drug | 1 drop 1 hour before intravitreal injection |
|
|
| Anterior chamber paracentesis | Procedure | Immediately after bevacizumab injection |
|
| ID | Term |
|---|---|
| D008268 | Macular Degeneration |
| D003930 | Diabetic Retinopathy |
| ID | Term |
|---|---|
| D012162 | Retinal Degeneration |
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
| D003925 | Diabetic Angiopathies |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D048909 | Diabetes Complications |
| D003920 | Diabetes Mellitus |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000086 | Acetazolamide |
| D000068438 | Brimonidine Tartrate |
| ID | Term |
|---|---|
| D013830 | Thiadiazoles |
| D013844 | Thiazoles |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D011810 | Quinoxalines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided